Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23628598 | 0.91 | TLR9 (0.39) | TLR9TLR8TLR7P2RX4ALDH1A1 | |
| SCHEMBL30309752 | 0.79 | HTR3A (0.42) | ALDH1A1 | |
| SCHEMBL23091664 | 0.77 | SSTR4 (0.48) | — | |
| SCHEMBL30282949 | 0.77 | POLB (0.47) | P2RX4ALDH1A1KDM4EPOLB | |
| SCHEMBL30382691 | 0.75 | TLR9 (0.39) | TLR9TLR8TLR7P2RX4ALDH1A1 | |
| SCHEMBL30309803 | 0.72 | SSTR4 (0.34) | — | |
| SCHEMBL30382788 | 0.71 | POLB (0.53) | P2RX4ALDH1A1POLB | |
| SCHEMBL18389931 | 0.70 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL30382846 | 0.70 | MC4R (0.35) | TLR9TLR8TLR7P2RX4ALDH1A1 | |
| SCHEMBL18712990 | 0.69 | POLB (0.65) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-03-18 | — | — | US | disclosed |
| CN-112654620-B | Novel pyrazolopyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-3847173-B1 | NOVEL PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3847173-A1 | NOVEL PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| CN-112654620-A | Novel pyrazolopyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | KCNJ1, KCNJ11, SSB | TLR9 2037/4885TLR8 3207/4885TLR7 1106/4885 |
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | KCNJ1, KCNJ11, SSB | TLR9 2037/4885TLR8 3207/4885TLR7 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.